Healthcare services company Chemed Corporation (NYSE:CHE) will be reporting results tomorrow after market hours. Here’s what you need to know.

Chemed beat analysts’ revenue expectations by 0.6% last quarter, reporting revenues of $640 million, up 9.2% year on year. It was a satisfactory quarter for the company, with a narrow beat of analysts’ full-year EPS guidance estimates.

Is Chemed a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Chemed’s revenue to grow 8.9% year on year to $641.8 million, improving from the 5.2% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $5.55 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Chemed has missed Wall Street’s revenue estimates six times over the last two years.

Looking at Chemed’s peers in the healthcare providers & services segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Quest delivered year-on-year revenue growth of 12.1%, beating analysts’ expectations by 1.3%, and Elevance Health reported revenues up 14.5%, topping estimates by 5%.

Read our full analysis of Quest’s results here and Elevance Health’s results here.

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.